Medicina
Departamento
National Cancer Center
Plainview, Estados UnidosPublicaciones en colaboración con investigadores/as de National Cancer Center (9)
2024
-
Canakinumab as Adjuvant Therapy in Patients With Completely Resected Non-Small-Cell Lung Cancer: Results From the CANOPY-A Double-Blind, Randomized Clinical Trial
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 42, Núm. 2, pp. 180-191
2020
-
Health-Related Quality of Life in MONARCH 3: Abemaciclib plus an Aromatase Inhibitor as Initial Therapy in HR+, HER2− Advanced Breast Cancer
Oncologist, Vol. 25, Núm. 9, pp. e1346-e1354
-
Pediatric NMOSD: A Review and Position Statement on Approach to Work-Up and Diagnosis
Frontiers in Pediatrics, Vol. 8
2018
-
Bevacizumab-based first-line chemotherapy in elderly patients with metastatic colorectal cancer: An individual patient data based meta-analysis
Oncotarget, Vol. 9, Núm. 12, pp. 10272-10283
-
Buparlisib plus fulvestrant in postmenopausal women with hormone-receptor-positive, HER2-negative, advanced breast cancer progressing on or after mTOR inhibition (BELLE-3): a randomised, double-blind, placebo-controlled, phase 3 trial
The Lancet Oncology, Vol. 19, Núm. 1, pp. 87-100
-
Reply to 'the St Gallen international expert consensus on the primary therapy of early breast cancer 2017: Te point of view of an international panel of experts in radiation oncology' by Kirova et al.
Annals of Oncology
2017
-
De-escalating and escalating treatments for early-stage breast cancer: The St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017
Annals of Oncology, Vol. 28, Núm. 8, pp. 1700-1712
2015
-
Afatinib alone or afatinib plus vinorelbine versus investigator's choice of treatment for HER2-positive breast cancer with progressive brain metastases after trastuzumab, lapatinib, or both (LUX-Breast 3): A randomised, open-label, multicentre, phase 2 trial
The Lancet Oncology, Vol. 16, Núm. 16, pp. 1700-1710
2013
-
A phase two randomised trial of neratinib monotherapy versus lapatinib plus capecitabine combination therapy in patients with HER2+ advanced breast cancer
European Journal of Cancer, Vol. 49, Núm. 18, pp. 3763-3772